Page 197 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology
Research on hypoxia and ECM in cancer

doi: 10.1016/j.trecan.2016.10.016 doi: 10.1002/2211-5463.13330
39. Wong CCL, Zhang H, Gilkes DM, et al. Inhibitors of 49. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME,
hypoxia-inducible factor 1 block breast cancer metastatic Peppas NA, Langer R. Engineering precision nanoparticles
niche formation and lung metastasis. J Mol Med (Berl). for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124.
2012;90(7):803-815.
doi: 10.1038/s41573-020-0090-8
doi: 10.1007/s00109-011-0855-y
50. Panagi M, Voutouri C, Mpekris F, et al. TGF-β inhibition
40. Shirakihara T, Horiguchi K, Miyazawa K, et al. TGF‐β combined with cytotoxic nanomedicine normalizes triple
regulates isoform switching of FGF receptors and epithelial- negative breast cancer microenvironment towards anti-
mesenchymal transition. EMBO J. 2011;30(4):783-795. tumor immunity. Theranostics. 2020;10(4):1910-1922.

doi: 10.1038/emboj.2010.351 doi: 10.7150/thno.36936
41. Wu MJ, Chen YS, Kim MR, et al. Epithelial-mesenchymal 51. Shen Z, Ma Q, Zhou X, et al. Strategies to improve
transition directs stem cell polarity via regulation of photodynamic therapy efficacy by relieving the tumor
mitofusin. Cell Metab. 2019;29(4):993-1002.e1006. hypoxia environment. NPG Asia Mater. 2021;13(1):39.
doi: 10.1016/j.cmet.2018.11.004 52. Zhang C, Qin WJ, Bai XF, Zhang XZ. Nanomaterials to
relieve tumor hypoxia for enhanced photodynamic therapy.
42. Emami Nejad A, Najafgholian S, Rostami A, et al. The role of Nano Today. 2020;35:100960.
hypoxia in the tumor microenvironment and development
of cancer stem cell: A novel approach to developing doi: 10.1016/j.phrs.2022.106551
treatment. Cancer Cell Int. 2021;21(1):62. 53. Zhang T, Wang X, Wang D, et al. Synergistic effects of
doi: 10.1186/s12935-020-01719-5 photodynamic therapy and chemotherapy: Activating
the intrinsic/extrinsic apoptotic pathway of anoikis for
43. Goodarzi H, Liu X, Nguyen HC, Zhang S, Fish L, Tavazoie triple-negative breast cancer treatment. Biomater Adv.
SF. Endogenous tRNA-derived fragments suppress 2024;160:213859.
breast cancer progression via YBX1 displacement. Cell.
2015;161(4):790-802. doi: 10.1016/j.bioadv.2024.213859
doi: 10.1016/j.cell.2015.02.053 54. Xiang L, Gilkes DM, Hu H, et al. Hypoxia-inducible factor
1 mediates TAZ expression and nuclear localization to
44. Gilkes DM, Bajpai S, Chaturvedi P, Wirtz D, Semenza GL. induce the breast cancer stem cell phenotype. Oncotarget.
Withdrawal: Hypoxia-inducible factor 1 (HIF-1) promotes 2014;5(24):12509-12527.
extracellular matrix remodeling under hypoxic conditions
by inducing P4HA1, P4HA2, and PLOD2 expression in doi: 10.18632/oncotarget.2997
fibroblasts. J Biol Chem. 2023;299(9):105144. 55. Bierbaumer L, Katschnig AM, Radic-Sarikas B, et al. YAP/
doi: 10.1074/jbc.M112.442939 TAZ inhibition reduces metastatic potential of Ewing
sarcoma cells. Oncogenesis. 2021;10(1):2.
45. Wang T, Gilkes DM, Takano N, et al. Hypoxia-inducible
factors and RAB22A mediate formation of microvesicles 56. Rytlewski JD, Scalora N, Garcia K, et al. Photodynamic
that stimulate breast cancer invasion and metastasis. Proc therapy using hippo pathway inhibitor verteporfin: A
Natl Acad Sci. 2014;111(31):E3234-E3242. potential dual mechanistic approach in treatment of soft
tissue sarcomas. Cancers (Basel). 2021;13(4):675.
doi: 10.1073/pnas.1410041111
doi: 10.3390/cancers13040675
46. Monteran L, Ershaid N, Doron H, et al. Chemotherapy-
induced complement signaling modulates 57. Wei L, Ma X, Hou Y, et al. Verteporfin reverses progestin
immunosuppression and metastatic relapse in breast cancer. resistance through YAP/TAZ-PI3K-Akt pathway in
Nat Commun. 2022;13(1):5797. endometrial carcinoma. Cell Death Discov. 2023;9(1):30.
doi: 10.1038/s41467-022-33598-x doi: 10.1038/s41420-023-01319-y
47. Kciuk M, Gielecińska A, Mujwar S, et al. Doxorubicin-an 58. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024.
agent with multiple mechanisms of anticancer activity. Cells. CA Cancer J Clin. 2024;74(1):12-49.
2023;12(4):659. doi: 10.3322/caac.21820
doi: 10.3390/cells12040659 59. Januškevičienė I, Petrikaitė V. Heterogeneity of breast
cancer: The importance of interaction between different
48. Sun Z, Zhou D, Yang J, Zhang D. Doxorubicin promotes
breast cancer cell migration and invasion via DCAF13. FEBS tumor cell populations. Life Sci. 2019;239:117009.
Open Bio. 2022;12(1):221-230. doi: 10.1016/j.lfs.2019.117009

Volume 9 Issue 1 (2025) 189 doi: 10.36922/ejmo.7116